Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Takeda acquiring Nimbus Therapeutics subsid for US$4 Billion

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Dec 13, 2022 7:21pm

170 Views

Post# 35169802

RE:RE:RE:RE:RE:RE:RE:Takeda acquiring Nimbus Therapeutics subsid for US$4 Billion

Business Description

Nimbus Lakshmi, which also operates under the name Nimbus, is located in Cambridge, Massachusetts. This organization primarily operates in the Druggists' Preparations (Pharmaceuticals) business / industry within the Chemicals and Allied Products sector. This organization has been operating for approximately 12 years. Nimbus Lakshmi is estimated to generate $1.2 million in annual revenues, and employs approximately 18 people at this single location. This organization is engaged in manufacturing activities at this facility.

<< Previous

Bullboard Posts

Next >>

How one company is disrupting PoC testing